Related Experiment Video
Updated: Jun 16, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
[Efficacy of atazanavir in simplification regimens]
Laura Zamora1, José María Gatell
1Servicio De Infecciones, Hospital Clínic, Barcelona, España. ZAMORA@clinic.ub.es
Enfermedades Infecciosas Y Microbiologia Clinica
|February 2, 2010
Summary
Atazanavir, a protease inhibitor, offers potent antiviral effects with a favorable pharmacokinetic profile, enabling once-daily dosing. It demonstrates excellent efficacy and tolerability, with benefits including reduced lipid levels and simplified treatment regimens for HIV patients.
Area of Science:
- Pharmacology
- Virology
- Immunology
Context:
- Atazanavir is a novel azapeptide protease inhibitor.
- Current HIV therapies often involve complex dosing regimens and potential metabolic side effects.
- There is a need for simplified and well-tolerated antiretroviral treatments.
Purpose:
- To evaluate the pharmacokinetic profile, antiviral efficacy, and safety of atazanavir.
- To assess the immunological and virological response in various patient populations.
- To explore atazanavir's potential for therapeutic simplification in HIV management.
Summary:
- Atazanavir exhibits a favorable pharmacokinetic profile, allowing for once-daily administration (two capsules) in combination with other antiretrovirals.
- The drug demonstrates strong antiviral efficacy and an excellent tolerance profile, with no significant increase in cholesterol or triglyceride levels.
- Excellent immunological and virological responses were observed in both naive patients and those with prior virological failure on other protease inhibitors.
Impact:
- Atazanavir presents an attractive option for simplifying HIV therapeutic regimens.
- Patients switching to atazanavir experience reductions in total cholesterol, HDL cholesterol, and triglycerides, alongside maintained virological suppression.
- Preliminary data suggest that atazanavir/ritonavir monotherapy may effectively maintain virological suppression in selected patients, further supporting treatment simplification.
More Related Videos
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:15Drug Dosage Regimen: Overview
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...